| Project/Area Number |
22659029
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
SUZUKI Hiroshi 東京大学, 医学部・附属病院, 教授 (80206523)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
HONMA Masashi 東京大学, 医学部・附属病院, 助教 (60401072)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,160,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥1,600,000 (Direct Cost: ¥1,600,000)
|
|---|
| Keywords | 薬剤反応性 / 特異体質性毒性 / プロテオーム / 免疫応答 / HLA / アバカビル / 生体分子 / 薬理学 |
|---|
| Research Abstract |
In abacavir hypersensitivity associated with HLA-B* 5701 genecareers, it is strongly suggested that the causal antigen is not peptides derived from protein adducts, as is assumed previously, but the abacavir itself. In the other cases caused by the same mechanism with abacavir hypersensitivity, the existing screening system based on the amount of protein adducts formation cannot find out the risk of adverse effect. The combination with the new screening system to discriminate if the drugs or their metabolites are presented as antigen will improve the prediction accuracy of idiosyncraticadverse effect
|
